DDInter489 DDInter899
Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA approved on October 14, 2011.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Deferiprone {u} (Compound) binds {v} (Gene) UGT1A6
Deferiprone {u} (Compound) upregulates {v} (Gene) BTK
Deferiprone {u} (Compound) is included by {v} (Pharmacologic Class) Iron Chelating Activity
Deferiprone {u} (Compound) downregulates {v} (Gene) HSPA8
Deferiprone {u} (Compound) causes {v} (Side Effect) Rash pustular
Deferiprone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium sulfate
Deferiprone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Deferiprone {u} may lead to a major life threatening interaction when taken with {v} Tioguanine
Deferiprone {u} may lead to a major life threatening interaction when taken with {v} Rucaparib
Deferiprone (Compound) binds UGT1A6 (Gene)
Deferiprone (Compound) upregulates BTK (Gene)
Deferiprone (Compound) is included by Iron Chelating Activity (Pharmacologic Class)
Deferiprone (Compound) downregulates HSPA8 (Gene)
Deferiprone (Compound) causes Rash pustular (Side Effect)
Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate
Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Deferiprone may lead to a major life threatening interaction when taken with Tioguanine
Deferiprone may lead to a major life threatening interaction when taken with Rucaparib